First-in-human evaluation of [211At]YF2 in patients with metastatic castration-resistant prostate cancer

Xiaoai Wu1, Yongzhao Xiang1, Michael R Zalutsky2

  • 1Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Insights

The novel alpha-particle therapy agent [211At]YF2 was safely administered to metastatic castration-resistant prostate cancer patients. This study confirmed clear delineation of metastatic lesions and favorable dosimetry, supporting further clinical development of [211At]YF2.

Area of Science:

  • Nuclear Medicine and Radiopharmaceutical Therapy
  • Oncology and Prostate Cancer Research
  • Medical Imaging and Dosimetry

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) remains a significant clinical challenge.
  • Prostate-specific membrane antigen (PSMA) is a validated target for mCRPC imaging and therapy.
  • Alpha-particle emitters offer potent therapeutic potential due to their high linear energy transfer.

Purpose of the Study:

  • To evaluate the safety, biodistribution, and dosimetry of the alpha-particle emitting PSMA inhibitor [211At]YF2 in a Phase 0 microdose study.
  • To assess the feasibility of using X-rays from 211At decay for imaging metastatic lesions in mCRPC patients.

Main Methods:

  • Initial biodistribution studies were conducted in CD-1 mice.
  • Three mCRPC patients with PSMA-positive metastases received intravenous [211At]YF2 (29.6-44.4 MBq).
  • Whole-body planar imaging and SPECT/CT scans were performed at various time points; safety and dosimetry were assessed using Rapid 3D-RD software.

Main Results:

  • [211At]YF2 was well-tolerated in patients, with all adverse events being Grade 2 or lower.
  • High initial uptake was observed in kidneys, bladder, salivary glands, and thyroid, followed by rapid clearance.
  • Metastatic lesions were clearly visualized, with dosimetry indicating a dose of 31.4 mGy/MBq to the most prominent metastasis and a kidney dose of 15.3 mGy/MBq.

Conclusions:

  • [211At]YF2 can be safely administered to mCRPC patients, enabling clear delineation of metastatic lesions.
  • The observed biodistribution and dosimetry profile of [211At]YF2 are favorable for clinical application.
  • These findings support the further clinical development of [211At]YF2 for mCRPC treatment.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.6K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
6.0K
Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation01:20

Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation

Evaluation of the teaching process enables the nurse to determine if the patient's learning needs were met and if training was effective. If the expected outcomes are not met, the care plan is revised, and additional education or reinforcement is provided. Nurses can ask questions after the session or obtain feedback to assess the patient's understanding of the topic.
Nurses can use several methods to evaluate patient outcomes. For example, oral questions can assess cognitive learning,...
2.6K
Equivalent Resistance01:16

Equivalent Resistance

In circuit analysis, situations often arise where resistors are neither in series nor parallel configurations. To tackle such scenarios, three-terminal equivalent networks like the wye (Y) (Figure 1 (a)) or tee (T) and delta (Δ) (Figure 1 (b)) or pi (π) networks come into play. These networks offer versatile solutions and are frequently encountered in various applications, including three-phase electrical systems, electrical filters, and matching networks.
998
Resistance and Conductance01:25

Resistance and Conductance

A conductor's DC resistance at a given temperature is influenced by its resistivity, length, and cross-sectional area. Resistivity is an inherent property of the conductor material, with annealed copper serving as the international standard for measurement. For instance, the resistivity of hard-drawn aluminum at 20 degrees Celsius is 61% of the standard conductivity of annealed copper.
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
527